A two-phased, randomized, double blind, placebo-controlled study of ECP002A (Δ9-THC) to determine safety, tolerability and efficacy in Multiple Sclerosis patients suffering from spasticity and pain.

A two-phased, randomized, double blind, placebo-controlled study of ECP002A (Δ9-THC) to determine safety, tolerability and efficacy in Multiple Sclerosis patients suffering from spasticity and pain. - Medical Cannabis Research Engine